Advancements in our understanding of cardiac conduction abnormalities and pathophysiology of congestive heart failure coupled with innovations in device manufacturing and programming have helped to create a demand for a plethora of newer cardiovascular devices over the past 3 decades. Appropriate use of cardiovascular implantable electronic devices (CIEDs) in carefully selected patients is asso...

Increased utilization of cardiovascular implantable electronic devices (CIED) has seen a corresponding rise in related infections. Non-tuberculosis mycobacteria (NTM) are rarely the cause. Treatment involves susceptibilities, antimicrobials, and device removal. This study presents a patient who underwent a biventricular implantable cardioverter defibrillator upgrade with a multi-drug resistant ...

The mechanisms underlying problematic cardiovascular device-associated infections are not understood. Because the outcome of the acute response to infection is largely dependent on the function of neutrophils, the persistence of these infections suggests that neutrophil function may be compromised because of cellular responses to shear stress. A rotating disk system was used to generate physiol...

Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction intracardiac electrodes, not only for systemic infections but also localized “pocket infections.” We evaluated the efficacy delivering “Continuous, In-situ-Targeted, ultra-high concentration Antibiotics” (CITA) into infected subcutaneous device-pocket, o...

Pharmacotherapy is a major treatment method in healthcare centers, and the injection of powdered drugs is among common pharmacotherapy techniques. Medication errors and nosocomial infections are among major health issues in the world. On the other hand, powdered drugs are widely used in hospitals; however, drug mixture is a very time-consuming process. The objective of this invention was to acc...